Dexcom, Inc. is an American healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| DXCM | DEXCOM INC | 2025-10-28 17:10:50 | 69 | -0.23 | -0.33 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DXCM | 0001093557 | DEXCOM INC | US2521311074 | 549300YSK3QDSFR5EU59 | 330857544 | Nasdaq | 3841 | Surgical & Medical Instruments & Apparatus | 1231 | DE | 6340 SEQUENCE DRIVE | SAN DIEGO | CA | 92121 | UNITED STATES | US | 8582000200 | 6340 SEQUENCE DRIVE, SAN DIEGO, CA, 92121 | 6340 SEQUENCE DRIVE, SAN DIEGO, CA, 92121 | — | — | 1999 | Kevin Sayer | 10,300 | http://dexcom.com | 45,300,000,000 | 410,400,000 | 392,155,265 | Dexcom, Inc. is an American healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland. | 2025-10-23 12:30:27 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 45,300,000,000 | -4,100,000,000 | -8.2996 | 390,772,018 | 5,256,597 | 1.3635 |
| 2023 | 49,400,000,000 | 20,300,000,000 | 69.7595 | 385,515,421 | -898,269 | -0.2325 |
| 2022 | 29,100,000,000 | -12,000,000,000 | -29.1971 | 386,413,690 | 289,348,056 | 298.0953 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Michael J. Brownevp | Chief Legal Officer | 2024 | 596,886 | 0 | 4,357,659 | 0 | 10,350 | 4,964,895 |
| Jacob S. Leachevp | Chief Operating Officer | 2024 | 682,498 | 0 | 5,229,163 | 0 | 10,610 | 5,922,271 |
| Kevin R. Sayer | Chief Executive Officer, Chairperson, President | 2024 | 1,157,254 | 0 | 14,536,111 | 0 | 135,432 | 15,828,797 |
| Jereme M. Sylvainevp | Chief Financial Officer | 2024 | 609,323 | 0 | 5,229,163 | 0 | 12,626 | 5,851,112 |
| Sadie M. Sternevp | Chief Human Resources Officer | 2024 | 539,791 | 0 | 4,357,659 | 0 | 11,038 | 4,908,488 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 10,300 |
| 2023 | 9,600 |
| 2022 | 7,600 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 4,033,000,000 | 3,622,300,000 | 2,909,800,000 |
| Cost Of Revenue | 1,594,800,000 | 1,333,400,000 | 1,026,700,000 |
| Gross Profit | 2,438,200,000 | 2,288,900,000 | 1,883,100,000 |
| Research And Development Expenses | 552,400,000 | 505,800,000 | 484,200,000 |
| General And Administrative Expenses | 1,285,800,000 | 1,185,400,000 | 1,000,200,000 |
| Operating Expenses | 1,838,200,000 | 1,691,200,000 | 1,491,900,000 |
| Operating Income | 600,000,000 | 597,700,000 | 391,200,000 |
| Net Income | 576,200,000 | 541,500,000 | 341,200,000 |
| Earnings Per Share Basic | 1.46 | 1.4 | 0.88 |
| Earnings Per Share Diluted | 1.42 | 1.3 | 0.82 |
| Weighted Average Shares Outstanding Basic | 393,600,000 | 386,000,000 | 389,400,000 |
| Weighted Average Shares Outstanding Diluted | 412,700,000 | 425,500,000 | 427,500,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 606,100,000 | 566,300,000 | 642,300,000 |
| Marketable Securities Current | 1,730,000,000 | 2,160,000,000 | 1,810,000,000 |
| Accounts Receivable | 1,005,700,000 | 973,900,000 | 713,300,000 |
| Inventories | 542,600,000 | 559,600,000 | 306,700,000 |
| Non Trade Receivables | 27,900,000 | 13,600,000 | 38,900,000 |
| Other Assets Current | 39,700,000 | 49,300,000 | 37,000,000 |
| Total Assets Current | 4,301,400,000 | 4,425,900,000 | 3,668,800,000 |
| Marketable Securities Non Current | 247,700,000 | 38,500,000 | — |
| Property Plant And Equipment | — | — | — |
| Other Assets Non Current | 173,000,000 | 75,000,000 | 47,100,000 |
| Total Assets Non Current | 1,402,700,000 | 1,184,500,000 | 1,722,900,000 |
| Total Assets | 6,484,500,000 | 6,264,500,000 | 5,391,700,000 |
| Accounts Payable | 345,300,000 | 276,400,000 | 237,900,000 |
| Deferred Revenue | 8,000,000 | 18,400,000 | 10,100,000 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 3,900,000 | 7,500,000 | — |
| Total Liabilities Current | 2,932,000,000 | 1,556,000,000 | 1,839,300,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | 147,900,000 | 125,600,000 | 128,300,000 |
| Total Liabilities Non Current | 1,449,900,000 | 2,639,900,000 | 1,420,600,000 |
| Total Liabilities | 4,381,900,000 | 4,195,900,000 | 3,259,900,000 |
| Common Stock | 400,000 | 400,000 | 400,000 |
| Retained Earnings | 1,597,600,000 | 1,021,400,000 | 479,900,000 |
| Accumulated Other Comprehensive Income | -8,000,000 | -16,700,000 | -11,600,000 |
| Total Shareholders Equity | 2,102,600,000 | 2,068,600,000 | 2,131,800,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 39,900,000 | 186,000,000 | 155,900,000 |
| Share Based Compensation Expense | 170,400,000 | 150,800,000 | 126,500,000 |
| Other Non Cash Income Expense | 47,300,000 | 83,900,000 | -34,700,000 |
| Change In Accounts Receivable | 35,000,000 | 260,100,000 | 199,900,000 |
| Change In Inventories | -12,400,000 | 252,600,000 | -49,300,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 211,700,000 | 466,500,000 | 295,100,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 989,500,000 | 748,500,000 | 669,500,000 |
| Purchases Of Marketable Securities | 2,576,300,000 | 3,200,400,000 | 2,266,300,000 |
| Sales Of Marketable Securities | 2,824,400,000 | 2,947,400,000 | 2,127,800,000 |
| Acquisition Of Property Plant And Equipment | 358,800,000 | 236,600,000 | 364,800,000 |
| Acquisition Of Business | 0 | 0 | 3,900,000 |
| Other Investing Activities | 15,500,000 | 17,600,000 | 14,300,000 |
| Cash From Investing Activities | -207,500,000 | -507,200,000 | -521,500,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 28,200,000 | 26,600,000 | 22,500,000 |
| Repurchase Of Common Stock | 750,000,000 | 688,700,000 | 557,700,000 |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | -13,000,000 | 1,500,000 | -17,300,000 |
| Cash From Financing Activities | -734,800,000 | -318,600,000 | -552,500,000 |
| Change In Cash | 39,800,000 | -75,800,000 | -410,300,000 |
| Cash At End Of Period | 606,100,000 | 566,300,000 | 642,300,000 |
| Income Taxes Paid | 198,000,000 | 212,300,000 | 114,200,000 |
| Interest Paid | 11,400,000 | 12,400,000 | 12,200,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | 1.46 | 1.4 | 0.88 |
| Price To Earnings Ratio | 53.2671 | 88.6357 | 128.6818 |
| Earnings Growth Rate | 4.2857 | 59.0909 | -45 |
| Price Earnings To Growth Ratio | 12.429 | 1.5 | -2.8596 |
| Book Value Per Share | 5.342 | 5.3591 | 5.4746 |
| Price To Book Ratio | 14.5583 | 23.1551 | 20.6847 |
| Ebitda | 829,000,000 | 960,100,000 | 629,900,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | — | — | — |
| Free Cash Flow | — | — | — |
| Return On Equity | 0.274 | 0.2618 | 0.1601 |
| One Year Beta | 0.3864 | 0.9241 | 1.5016 |
| Three Year Beta | 1.1898 | 1.3163 | 1.0745 |
| Five Year Beta | 1.0112 | 1.066 | 1.0694 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Ashley Euan A. | Director | 2025-10-24 | 7,166 | A | 7,166 |
| Malady Kyle | Director | 2025-09-05 | 667 | D | 22,667 |
| Stern Sadie | EVP, Chief HR Officer | 2025-09-04 | 1,466 | D | 105,223 |
| Sylvain Jereme M | EVP, Chief Financal Officer | 2025-09-02 | 4,824 | D | 118,657 |
| FOLETTA MARK G | Director | 2025-08-15 | 2,555 | D | 51,316 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Tina Smith | Senator | 2020-04-16 | Sale (Partial) | 2020-03-17 | Spouse | $250,001 - $500,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Jefferson Shreve | 2025-06-22 | IN06 | Purchase | 2025-05-08 | — | $15,001 - $50,000 |
| Jefferson Shreve | 2025-06-22 | IN06 | Sale | 2025-05-12 | — | $15,001 - $50,000 |
| Rob Bresnahan | 2025-06-09 | PA08 | Purchase | 2025-05-15 | — | $1,001 - $15,000 |
| Jefferson Shreve | 2025-05-08 | IN06 | Sale | 2025-04-07 | — | $15,001 - $50,000 |
| Rob Bresnahan | 2025-04-28 | PA08 | Sale | 2025-04-08 | — | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| QRG CAPITAL MANAGEMENT, INC. | 2025-09-30 | 1,662,783 | 24,711 | 67.2892 |
| WATERS PARKERSON & CO., LLC | 2025-09-30 | 23,851,075 | 354,452 | 67.29 |
| Fulcrum Capital LLC | 2025-09-30 | 2,679,421 | 39,819 | 67.29 |
| Arlington Trust Co LLC | 2025-09-30 | 9,421 | 140 | 67.2929 |
| Stephens Investment Management Group LLC | 2025-09-30 | 57,943,419 | 861,100 | 67.29 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Fidelity Rutland Square Trust II | 2025-08-31 | Strategic Advisers U.S. Total Stock Fund | FSAKX | 55,087 | 4,150,254.58 | 0.0051 |
| Fidelity Rutland Square Trust II | 2025-08-31 | Strategic Advisers Fidelity U.S. Total Stock Fund | FCTDX | 11,649 | 877,635.66 | 0.0005 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Series Total Market Index Fund | FCFMX | 547,201 | 41,226,123.34 | 0.0472 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Total Market Index Fund | FSKAX | 731,620 | 55,120,250.8 | 0.0473 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Nasdaq Composite Index Fund | FNCMX | 232,115 | 17,487,544.1 | 0.0836 |